

October 1, 2008

AnGes MG, Inc.

Substance Patent for a NF- κ B Decoy-Oligonucleotide Granted in Japan
- Covering AnGes MG's Decoy Sequence Currently Under Development -

AnGes MG, Inc. announces that a substance patent for its NF- κ B decoy-oligonucleotide now under development for the treatment of atopic dermatitis has been granted in Japan, and that the Patent Gazette (Patent No. 4159836) was issued.

This patent covers not only the use (indications) of the NF- κ B decoy oligonucleotide but also the substance itself, irrespective of its use. This patent strengthens the foundation of AnGes MG's clinical development project for the NF- κ B decoy oligonucleotide, including expanding the scope of its applications to other diseases.

Outside Japan, AnGes MG holds corresponding patents related to inflammatory diseases that effectively protect its international clinical development activities.

US (Medical use) Patent: No. US6262033

European (Medical use) Patent: No. EP824918B1

Japanese (Medical use) Patent: No. 3474879

The above patents are valid up to May 2016. When new drug approvals become granted in each country before that point, it is expected that the corresponding patent periods will be extended for a maximum of five additional years. This indicates that AnGes MG's NF- κ B decoy oligonucleotide development project is duly protected by appropriate patents.

In addition to the current patent, a succession of other medical-use patent applications, such as those for atopic dermatitis, psoriasis and rheumatic arthritis have been filed to expand the scope of clinical applications.

Preparation for the Phase III clinical trials of NF- κ B decoy oligonucleotide in the treatment of atopic dermatitis in Japan are underway and the medical-use patent for this indication has already been granted, with its patent period set valid until February 2022.